Skip to main content
. 2001 Oct 15;21(20):7919–7927. doi: 10.1523/JNEUROSCI.21-20-07919.2001

Fig. 4.

Fig. 4.

The 5-HT2A receptor antagonist MDL 100,907 reverses the inhibitory effect of DOI on the oxytocin (A) and the ACTH (B) responses to an 8-OH-DPAT (0.05 mg/kg, s.c.) challenge. The data represent the means ± SEM of 7–10 rats per group. *Significant difference from saline/8-OH-DPAT group (p < 0.01); #significant difference from DOI/8-OH-DPAT group (p < 0.01); three-way ANOVA and Newman–Keuls multiple range test.

HHS Vulnerability Disclosure